Blocking Adenosine/A2AR Pathway for Cancer Therapy
Adenosine is a metabolite produced abundantly in the tumor microenvironment, dampening immune response in inflamed tissues via adenosine A2A receptor (A2AR) which is widely expressed on immune cells, inhibiting anti-tumor immune response accordingly. Therefore, blocking adenosine signaling pathway is of potential to promote anti-tumor immunity. This review briefly introduces adenosine signaling pathway, describes its role in regulating tumor immunity and highlights A2AR blockade in cancer therapy. Prospective anti-tumor activity of adenosine/A2AR inhibition has been revealed by preclinical data, and a number of clinical tr...
Source: Chinese Journal of Lung Cancer - July 20, 2022 Category: Cancer & Oncology Source Type: research
MUC16: The Novel Target for Tumor Therapy
This article will review the mechanism of MUC16 in tumor genesis and progression, and focus on the research actuality of MUC16 in tumor therapy. This article also provides references for subsequent tumor therapy studies targeting MUC16.
DOI: 10.3779/j.issn.1009-3419.2022.101.31 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - July 20, 2022 Category: Cancer & Oncology Source Type: research
Considerations on Clinical Development and Regulatory of the Oversea License-in
Anti-tumor Drugs
With the boom of China ' s innovative pharmaceutical industry, licensing-in model has gradually become an important research and development model for innovative pharmaceutical companies. The in-licensed drugs at different stages need different research and development (R&D) strategy in China. The pharmaceutical companies take the responsibility to comprehensively collate the oversea clinical data and conduct a detailed analysis of clinical pharmacology, safety, efficacy and ethnic sensitivity. Clinical R&D strategy should be made based on the results of the above data and analysis. We encourage high-quality drugs which fi...
Source: Chinese Journal of Lung Cancer - July 20, 2022 Category: Cancer & Oncology Source Type: research
Consensus of Chinese Experts on Medical Treatment of Advanced Lung Cancer
in the Elderly (2022 Edition)
DOI: 10.3779/j.issn.1009-3419.2022.101.25 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - June 24, 2022 Category: Cancer & Oncology Source Type: research
DNA Damage Repair System and Antineoplastic Agents in Lung Cancer
DNA damage repair (DDR) system plays an important role in maintaining of genomic stability. Accumulation of DNA lesions or deficiency of DDR system could drive tumorigenesis as well as promote tumor progression; meanwhile, they could also provide therapeutic opportunities and targets. Of all the antineoplastic agents of lung cancers, many of them targeted or were associated with DNA damage and repair pathways, such as chemotherapies and antibody-drug conjugates which were designed directly causing DNA damages, targeted drugs inhibiting DNA repair pathways, and immune-checkpoint inhibitors. In this review, we described the ...
Source: Chinese Journal of Lung Cancer - June 20, 2022 Category: Cancer & Oncology Source Type: research
Clinical Progress in the Immunotherapy of Small Cell Lung Cancer
This article aimed to review the clinical progress in immunotherapy of small cell lung cancer.
DOI: 10.3779/j.issn.1009-3419.2022.102.15 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - June 20, 2022 Category: Cancer & Oncology Source Type: research
Research Progress of Pharmacological Therapy and Nutritional Support for Cachexia
in Lung Cancer Patients
This article reviews the application of drug therapy and nutritional support in lung cancer patients, and looks forward to the research direction of cachexia control in lung cancer patients.
DOI: 10.3779/j.issn.1009-3419.2022.101.21 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - June 20, 2022 Category: Cancer & Oncology Source Type: research
Symptomatic Radiation Pneumonitis in NSCLC Patients Receiving EGFR-TKIs and Concurrent Once-daily Thoracic Radiotherapy: Predicting the Value of Clinical and Dose-volume Histogram Parameters
Background and objectives: The incidence of symptomatic radiation pneumonitis (RP) and its relationship with dose-volume histogram (DVH) parameters in non-small cell lung cancer (NSCLC) patients receiving epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and concurrent once-daily thoracic radiotherapy (TRT) remain unclear. We aim to analyze the values of clinical factors and dose-volume histogram (DVH) parameters to predict the risk for symptomatic RP in these patients.
Methods: Between 2011 and 2019, we retrospectively analyzed and identified 85 patients who had received EGFR-TKIs and once-daily T...
Source: Chinese Journal of Lung Cancer - June 20, 2022 Category: Cancer & Oncology Source Type: research
Analysis of the Efficacy of Immunotherapy in Elderly Patients with Lung Cancer
Conclusion The efficacy and safety of immunotherapy in elderly patients were similar to those in younger patients, and PFS was superior in the first-line immunotherapy. Further prospective studies are still needed to explore predictors of immunotherapy in elderly NSCLC patients.
DOI: 10.3779/j.issn.1009-3419.2022.102.16 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - June 20, 2022 Category: Cancer & Oncology Source Type: research
Variation of Main Postoperative Symptoms in Lung Cancer Patients
Undergoing Video-assisted Thoracoscopic Surgery
Conclusion The main postoperative symptoms of lung cancer patients with pulmonary nodules are pain and cough. The incidence and severity of pain decreases with time, and the incidence of cough increases but the severity decreased gradually.
DOI: 10.3779/j.issn.1009-3419.2022.101.23 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - June 20, 2022 Category: Cancer & Oncology Source Type: research
The Expression of RTN1 in Lung Adenocarcinoma and
Its Effect on Immune Microenvironment
Conclusion RTN1 may act as a tumor suppressor gene and indicate better prognosis. Furthermore, RTN1 is associated with immune infiltration that may be involved in the immunotherapy response in LUAD. However, the related mechanism needs further research. DOI: 10.3779/j.issn.1009-3419.2022.105.02 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - June 20, 2022 Category: Cancer & Oncology Source Type: research
Successful Rescue of Acute Exacerbation of Idiopathic Pulmonary Fibrosis after Surgery for Lung Cancer: Case Report
Idiopathic Pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic interstitial lung disease with unknown cause, which is closely related to lung cancer. A serious complication called Acute exacerbation of IPF (AE-IPF) is prone to occur after lung resection. It progresses rapidly without effective treatment and has a poor prognosis. A typical case of AE-IPF after lung cancer surgery was reported, and its clinical characteristics, imaging features, diagnosis and treatment were summarized.
DOI: 10.3779/j.issn.1009-3419.2022.102.13 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - May 19, 2022 Category: Cancer & Oncology Source Type: research
Research Progress of Mesenchymal Stem Cells and Their Exosomes on Tumors
In China, malignant tumor is the main cause of death in both urban and rural areas. Mesenchymal stem cells (MSCs) have multidirectional differentiation potential, self-renewal ability and good immunomodulatory properties. Exosomes, as important paracrine substances of MSCs, mediate information exchange and transmission between cells in tumor microenvironment and influence the occurrence and development of tumors. Recently, conflicting findings have been reported on the effects of MSCs and their exosomes on tumors. On the one hand, MSCs and their exosomes are tumorigenic and can target specific sites to inhibit tumor growth...
Source: Chinese Journal of Lung Cancer - May 19, 2022 Category: Cancer & Oncology Source Type: research
Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
Epidermal growth factor receptor (EGFR) exon 20 insertion mutations are the third most prevalent activating EGFR mutation in non-small cell lung cancer (NSCLC), accounting for 5%-12% of all EGFR mutations in NSCLC cases. Patients harboring EGFR exon 20 insertion mutations exhibit similar clinical characteristics except for worse prognosis as compared to those with ‘classic’ EGFR mutations. EGFR exon 20 insertion mutations are considered as a heterogeneous class of alterations that cause different conformational changes in EGFR. The majority of mutations (almost 90% of cases) is positioned in the loop that immediately f...
Source: Chinese Journal of Lung Cancer - May 19, 2022 Category: Cancer & Oncology Source Type: research
Treatment Sequencing Strategies in Lung Cancer
Conclusions The screening predictability in more patients, smoking reduction, early diagnosis, better disease understanding and individualized, more effective and tolerable therapeutics are related to an increasing in overall survival and quality of life. In the near future improvement of personalized therapy in precision medicine is expected, enhancing new predictive biomarkers, optimal doses and o ptimal treatment sequencing as well as anti-cancer vaccines development. DOI: 10.3779/j.issn.1009-3419.2022.104.01 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - May 19, 2022 Category: Cancer & Oncology Source Type: research
